Bayer-receives-approval-for-Vitrakvi-in-Japan

Precision oncology treatment Vitrakvi™ (larotrectinib) approved for the treatment of NTRK fusion-positive advanced or recurrent solid tumors / In clinical studies, larotrectinib demonstrated high response rates and durable responses in adults and children with TRK fusion cancer, including responses and a high disease control rate in primary central nervous system (CNS) tumors / The Japanese marketing authorization of Vitrakvi follows the approval of the expanded use of FoundationOne®CDx, a comprehensive genomic profiling (CGP) test, in Japan for use as a companion diagnostic (CDx) to identify patients with TRK fusion cancer who could benefit from treatment with Vitrakvi
Source: Bayer Company News - Category: Pharmaceuticals Source Type: news